Amphastar Pharm Shows Rising Relative Strength; Still Shy Of Key Benchmark

Blockhead

2024-10-17

In a welcome move, Amphastar Pharm (AMPH) saw its Relative Strength Rating improve from 67 to 75 on Thursday.

↑ X

What Are The Magnificent Seven Stocks?

See All Videos

NOW PLAYING What Are The Magnificent Seven Stocks?

IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.

Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 in the early stages of their moves. See if Amphastar Pharm can continue to rebound and hit that benchmark.

Can You Really Time The Stock Market?

Amphastar Pharm is building a double bottom with a 65.92 entry. See if it can clear the breakout price in volume at least 40% higher than normal. It's a later-stage pattern, and investors should be aware that those involve more risk.

EPS growth fell last quarter from 68% to 45%, but sales rose from 23% to 25%. The company is expected to report its latest earnings and sales numbers on or around Nov. 4.

Amphastar Pharm earns the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics (ADMA), Catalyst Pharmaceuticals (CPRX) and United Therapeutics (UTHR) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2476170292"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2476170292\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2476170292?lang=zh_TW&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU1-150x150.jpg","is_english":true,"pubTime":"2024-10-17 15:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476170292","market":"sg","top_or_hot":-1,"title":"Amphastar Pharm Shows Rising Relative Strength; Still Shy Of Key Benchmark","media":"Blockhead","content":"<html><body><div>\n<p>In a welcome move, <b>Amphastar Pharm</b> (AMPH) saw its Relative Strength Rating improve from 67 to 75 on Thursday.</p>\n<span>\n<span>\n<span jw-video-key=\"BPyynZxR\" vid-authors=\"ALEXIS GARCIA, MATT KRANTZ\" vid-cat=\"IBD Explains\" vid-date=\"07/24/2023\" vid-date-tmsp=\"1690178424\" vid-dom-id=\"8532639-67112c0602061\" vid-id=\"8532639\" vid-image=\"https://www.investors.com/wp-content/uploads/2023/07/BPyynZxR-640x360.jpg\" vid-name=\"What Are The Magnificent Seven Stocks?\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/BPyynZxR.m3u8\" vid-width=\"50\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span></span>\n<div>\n<div>\nWhat Are The Magnificent Seven Stocks?\n</div>\n<div>\nSee All Videos\n</div>\n</div>\n</span>\n<span>\n<span>NOW PLAYING</span>\n<span>What Are The Magnificent Seven Stocks?</span>\n</span>\n</span>\n</span>\n</span>\n<p>IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.</p>\n<p>Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 in the early stages of their moves. See if Amphastar Pharm can continue to rebound and hit that benchmark.</p>\n<hr/>\n<p>Can You Really Time The Stock Market? </p>\n<hr/>\n<p>Amphastar Pharm is building a double bottom with a 65.92 entry. See if it can clear the breakout price in volume at least 40% higher than normal. It's a later-stage pattern, and investors should be aware that those involve more risk.</p>\n<div><div></div></div>\n<p>EPS growth fell last quarter from 68% to 45%, but sales rose from 23% to 25%. The company is expected to report its latest earnings and sales numbers on or around Nov. 4.</p>\n<p>Amphastar Pharm earns the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. <b>ADMA Biologics</b> (ADMA), <b>Catalyst Pharmaceuticals</b> (CPRX) and <b>United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></b> (UTHR) are among the top 5 highly rated stocks within the group.</p>\n<p><strong>RELATED:</strong></p>\n<p>Biotech And Pharmaceutical Industry And Stock News</p>\n<p>IBD Stock Rating Upgrades: Rising Relative Strength</p>\n<p>Why Should You Use IBD's Relative Strength Rating?</p>\n<p>How Relative Strength Line Can Help You Judge A Stock</p>\n<p>Ready To Grow Your Investing Skills? Join An IBD Meetup Group!</p>\n</div></body></html>","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amphastar Pharm Shows Rising Relative Strength; Still Shy Of Key Benchmark</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmphastar Pharm Shows Rising Relative Strength; Still Shy Of Key Benchmark\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Blockhead</strong><span class=\"h-time small\">2024-10-17 15:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<p>In a welcome move, <b>Amphastar Pharm</b> (AMPH) saw its Relative Strength Rating improve from 67 to 75 on Thursday.</p>\n<span>\n<span>\n<span jw-video-key=\"BPyynZxR\" vid-authors=\"ALEXIS GARCIA, MATT KRANTZ\" vid-cat=\"IBD Explains\" vid-date=\"07/24/2023\" vid-date-tmsp=\"1690178424\" vid-dom-id=\"8532639-67112c0602061\" vid-id=\"8532639\" vid-image=\"https://www.investors.com/wp-content/uploads/2023/07/BPyynZxR-640x360.jpg\" vid-name=\"What Are The Magnificent Seven Stocks?\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/BPyynZxR.m3u8\" vid-width=\"50\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span></span>\n<div>\n<div>\nWhat Are The Magnificent Seven Stocks?\n</div>\n<div>\nSee All Videos\n</div>\n</div>\n</span>\n<span>\n<span>NOW PLAYING</span>\n<span>What Are The Magnificent Seven Stocks?</span>\n</span>\n</span>\n</span>\n</span>\n<p>IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.</p>\n<p>Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 in the early stages of their moves. See if Amphastar Pharm can continue to rebound and hit that benchmark.</p>\n<hr/>\n<p>Can You Really Time The Stock Market? </p>\n<hr/>\n<p>Amphastar Pharm is building a double bottom with a 65.92 entry. See if it can clear the breakout price in volume at least 40% higher than normal. It's a later-stage pattern, and investors should be aware that those involve more risk.</p>\n<div><div></div></div>\n<p>EPS growth fell last quarter from 68% to 45%, but sales rose from 23% to 25%. The company is expected to report its latest earnings and sales numbers on or around Nov. 4.</p>\n<p>Amphastar Pharm earns the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. <b>ADMA Biologics</b> (ADMA), <b>Catalyst Pharmaceuticals</b> (CPRX) and <b>United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></b> (UTHR) are among the top 5 highly rated stocks within the group.</p>\n<p><strong>RELATED:</strong></p>\n<p>Biotech And Pharmaceutical Industry And Stock News</p>\n<p>IBD Stock Rating Upgrades: Rising Relative Strength</p>\n<p>Why Should You Use IBD's Relative Strength Rating?</p>\n<p>How Relative Strength Line Can Help You Judge A Stock</p>\n<p>Ready To Grow Your Investing Skills? Join An IBD Meetup Group!</p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.investors.com/ibd-data-stories/amphastar-pharm-shows-rising-relative-strength-still-shy-of-key-benchmark/\">Blockhead</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文藝復興科技持倉","start_time":0,"source_url":"https://www.investors.com/ibd-data-stories/amphastar-pharm-shows-rising-relative-strength-still-shy-of-key-benchmark/","article_id":"2476170292","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU1-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476170292","pubTimestamp":1729148400,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Amphastar Pharm shows improving price performance, earning an upgrade to its IBD Relative Strength Rating","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4588":"碎股","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4557":"大麻股","ADMA":"ADMA Biologics Inc","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","UTHR":"美国联合医疗","BK4585":"ETF&股票定投概念","BK4139":"生物科技","AMPH":"Amphastar Pharmaceuticals","BK4007":"制药","CPRX":"Catalyst Pharmaceutical Partners"},"translate_title":"Amphastar Pharm显示出不断上升的相对实力；仍低于关键基准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1,"AMPH":1,"CPRX":1,"UTHR":1},"content_text":"In a welcome move, Amphastar Pharm (AMPH) saw its Relative Strength Rating improve from 67 to 75 on Thursday.\n\n\n\n↑\nX\n\n\n\n\nWhat Are The Magnificent Seven Stocks?\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nWhat Are The Magnificent Seven Stocks?\n\n\n\n\nIBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.\nOver 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 in the early stages of their moves. See if Amphastar Pharm can continue to rebound and hit that benchmark.\n\nCan You Really Time The Stock Market? \n\nAmphastar Pharm is building a double bottom with a 65.92 entry. See if it can clear the breakout price in volume at least 40% higher than normal. It's a later-stage pattern, and investors should be aware that those involve more risk.\n\nEPS growth fell last quarter from 68% to 45%, but sales rose from 23% to 25%. The company is expected to report its latest earnings and sales numbers on or around Nov. 4.\nAmphastar Pharm earns the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics (ADMA), Catalyst Pharmaceuticals (CPRX) and United Therapeutics (UTHR) are among the top 5 highly rated stocks within the group.\nRELATED:\nBiotech And Pharmaceutical Industry And Stock News\nIBD Stock Rating Upgrades: Rising Relative Strength\nWhy Should You Use IBD's Relative Strength Rating?\nHow Relative Strength Line Can Help You Judge A Stock\nReady To Grow Your Investing Skills? Join An IBD Meetup Group!","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}